SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: david james who wrote (966)6/20/2000 4:50:00 PM
From: Bosco  Read Replies (1) | Respond to of 1298
 
Hi david, good find. Thx. CEGE is at a technical crossroad around here. A break above this 28 level will likely to propel her up north of 30. Maybe we need some volume to convince people the rocketship is ready :)

best, Bosco



To: david james who wrote (966)6/20/2000 8:34:00 PM
From: tom pope  Read Replies (1) | Respond to of 1298
 
>>Not sure why CEGE has yet to respond <<

Although the book value has to be adjusted by the tax implications of a disposition of ABGX stock, it is indeed baffling.

On a raw pre-tax basis and using the 3/31 cash and equivalents figures, the company is selling for zilch.

I have been adding, but with fear and trembling. Whenever I think something is a slam dunk, it almost never is.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News